Dr. Muss on Cardiac Function in Breast Cancer Patients

Hyman B. Muss, MD
Published: Thursday, Apr 03, 2014

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses maximizing cardiac function in patients with breast cancer.

Muss says oncologists are aware of cardiac toxicity from their experience with anthracyclines. With the advent of anti-HER2 therapy, oncologists now have a larger group of issues related to cardiac toxicity and research has been conducted on the prevention of such toxicities. Studies involving the use of preventative beta-blockers and ACE inhibitors in patients who have a high risk of cardiac disease have demonstrated promise.

Muss believes that oncologists need to be aware of cardiac toxicities in patients taking anti-HER2 therapy and should work proactively with cardiologists to treat patients appropriately.

Hyman B. Muss, MD, professor of oncology, University of North Carolina, director, Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses maximizing cardiac function in patients with breast cancer.

Muss says oncologists are aware of cardiac toxicity from their experience with anthracyclines. With the advent of anti-HER2 therapy, oncologists now have a larger group of issues related to cardiac toxicity and research has been conducted on the prevention of such toxicities. Studies involving the use of preventative beta-blockers and ACE inhibitors in patients who have a high risk of cardiac disease have demonstrated promise.

Muss believes that oncologists need to be aware of cardiac toxicities in patients taking anti-HER2 therapy and should work proactively with cardiologists to treat patients appropriately.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x